Dataset Information

Design, synthesis and structure-activity studies of rhodanine derivatives as HIV-1 integrase inhibitors.

ABSTRACT: Raltegravir was the first HIV-1 integrase inhibitor that gained FDA approval for use in the treatment of HIV-1 infection. Because of the emergence of IN inhibitor-resistant viral strains, there is a need to identify innovative second-generation IN inhibitors. Previously, we identified 2-thioxo-4-thiazolidinone (rhodanine)-containing compounds as IN inhibitors. Herein, we report the design, synthesis and docking studies of a series of novel rhodanine derivatives as IN inhibitors. All these compounds were further tested against human apurinic/apyrimidinic endonuclease 1 (APE1) to determine their selectivity. Two compounds showed significant cytotoxicity in a panel of human cancer cell lines. Taken together, our results show that rhodanines are a promising class of compounds for developing drugs with antiviral and anticancer properties.

SUBMITTER: Ramkumar K

PROVIDER: S-EPMC6264390 | biostudies-literature | 2010 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Design, synthesis and structure-activity studies of rhodanine derivatives as HIV-1 integrase inhibitors.

Ramkumar Kavya K Yarovenko Vladimir N VN Nikitina Alexandra S AS Zavarzin Igor V IV Krayushkin Mikhail M MM Kovalenko Leonid V LV Esqueda Adrian A Odde Srinivas S Neamati Nouri N

Molecules (Basel, Switzerland) 20100601 6

Raltegravir was the first HIV-1 integrase inhibitor that gained FDA approval for use in the treatment of HIV-1 infection. Because of the emergence of IN inhibitor-resistant viral strains, there is a need to identify innovative second-generation IN inhibitors. Previously, we identified 2-thioxo-4-thiazolidinone (rhodanine)-containing compounds as IN inhibitors. Herein, we report the design, synthesis and docking studies of a series of novel rhodanine derivatives as IN inhibitors. All these compou ...[more]

PMID: 20657419

Dataset Information

Design, synthesis and structure-activity studies of rhodanine derivatives as HIV-1 integrase inhibitors.

Publications

Design, synthesis and structure-activity studies of rhodanine derivatives as HIV-1 integrase inhibitors.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Similar Datasets

Structure-Activity Relationship Studies of HIV-1 Integrase Oligonucleotide Inhibitors.
| S-EPMC4018115 | biostudies-literature

Novel quinolinonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, and biological activities.
| S-EPMC2646871 | biostudies-other

Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.
| S-EPMC4486254 | biostudies-literature

Structure-based design, synthesis, and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones.
| S-EPMC2996262 | biostudies-literature

Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, biological activities, and mechanism of action.
| S-EPMC2602756 | biostudies-literature

Design and synthesis of bis-amide and hydrazide-containing derivatives of malonic acid as potential HIV-1 integrase inhibitors.
| S-EPMC6245433 | biostudies-literature

Design, synthesis and structure-activity relationship (SAR) studies of 2,4-disubstituted pyrimidine derivatives: dual activity as cholinesterase and A?-aggregation inhibitors.
| S-EPMC3066269 | biostudies-literature

Design, Synthesis and Biological Assessment of Rhodanine-Linked Benzenesulfonamide Derivatives as Selective and Potent Human Carbonic Anhydrase Inhibitors.
| S-EPMC9697818 | biostudies-literature

HIV-1 Reverse Transcriptase/Integrase Dual Inhibitors: A Review of Recent Advances and Structure-activity Relationship Studies.
| S-EPMC8457747 | biostudies-literature

Design, Synthesis, and Biological Evaluation of 1,2-Dihydroisoquinolines as HIV-1 Integrase Inhibitors.
| S-EPMC4601057 | biostudies-literature